NDA 050715 · Novartis
Neoral
Cyclosporine · Oral · Calcineurin Inhibitor Immunosuppressant
Last checked: Nov 20, 2026Latest source record: Sep 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Jul 14, 1995
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,166
250 Phase 3, 65 recruiting
FAERS reports
71,471
65,437 serious, 13,460 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Only physicians experienced in management of systemic immunosuppressive therapy for the indicated disease should prescribe Neoral. At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Neoral. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. Neoral, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other...
What it is approved for
From the label in effect Aug 10, 2026.
INDICATIONS AND USAGE Kidney, Liver, and Heart Transplantation Neoral is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Neoral has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Neoral is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Neoral can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Neoral is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with Neoral as with other therapies upon cessation of treatment.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 14, 1995 Original approval · Type 3 - New Dosage Form
3 products under this application
- NEORAL · CYCLOSPORINE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- NEORAL · CYCLOSPORINE 25MG · CAPSULE, ORAL · Prescription · TE AB1
- NEORAL · CYCLOSPORINE 100MG · CAPSULE, ORAL · Prescription · TE AB1
Clinical trials
Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.
University Hospital, AngersGovernment (non-federal)
NCT02416388 · 3,100 participants (planned) · Start Jan 2015 · Primary completion Jul 30, 2025
Drug: Idarubicin; Daunorubicin and 8 more · For: Acute Myeloid Leukemia (AML)
Sites: Amiens, France; Angers, France; Argenteuil, France · 56 sites in all
- Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate EpisodesPivotal-lookingTerminated
Atrial Fibrillation NetworkAcademic, hospital or other
NCT02618577 · 2,608 participants · Start Feb 2016 · Primary completion Dec 31, 2022
Drug: Edoxaban; ASA · For: Atrial High Rate Episodes
Sites: Multiple Locations, Austria; Multiple Locations, Belgium; Multiple Locations, Bulgaria · 18 sites in all
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
Merck KGaA, Darmstadt, GermanyIndustry
NCT00249808 · 1,266 participants · Start Dec 13, 2004 · Primary completion Jan 25, 2007
Drug: Efalizumab - anti-CD11a recombinant human monoclonal antibody · For: Psoriasis
Sites: Feltham, United Kingdom
- Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60aPivotal-lookingCompleted
University of LeipzigAcademic, hospital or other
NCT01497002 · 1,222 participants · Start Apr 2005 · Primary completion Jul 18, 2018
Drug: Cytarabine; human stem cells · For: Acute Myeloid Leukaemia
Sites: Leipzig, Germany
- Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to FluorouracilPivotal-lookingCompleted
University of LeedsAcademic, hospital or other
NCT00389870 · 1,198 participants · Start Dec 2006
Drug: panitumumab; cyclosporine and 1 more · For: Colorectal Cancer
Sites: Bournemouth, United Kingdom; Brighton, United Kingdom; Bristol, United Kingdom · 33 sites in all
- Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) PatientsPivotal-lookingCompleted
Hospices Civils de LyonAcademic, hospital or other
NCT01502774 · 970 participants · Start Apr 2011 · Primary completion Feb 2015
Drug: Injection of Cyclosporin; Placebo · For: ST Elevation Acute Myocardial Infarction
Sites: Bruges, Belgium; Charleroi, Belgium; Edegem, Belgium · 45 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective9,115
- off label use8,353
- product use in unapproved indication4,122
- pyrexia3,717
- pneumonia2,869
- diarrhoea2,746
- condition aggravated2,649
- nausea2,525
- cytomegalovirus infection2,257
- fatigue2,098
- hypertension2,081
- renal impairment2,032
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,339 |
| 2005 | 1,287 |
| 2006 | 1,416 |
| 2007 | 1,387 |
| 2008 | 2,313 |
| 2009 | 2,478 |
| 2010 | 2,263 |
| 2011 | 3,028 |
| 2012 | 2,467 |
| 2013 | 1,352 |
| 2014 | 1,556 |
| 2015 | 1,530 |
| 2016 | 1,826 |
| 2017 | 2,279 |
| 2018 | 2,692 |
| 2019 | 3,509 |
| 2020 | 4,673 |
| 2021 | 4,283 |
| 2022 | 5,861 |
| 2023 | 5,833 |
| 2024 | 7,165 |
| 2025 | 6,275 |
| 2026 | 4,647 |
Recalls
1 FDA enforcement reports for this application.
Sep 16, 2022 · Class II · Terminated
CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Neoral (Cyclosporine, Modified)
2024 spending
$925K
Beneficiaries
264
1,341 claims
Per beneficiary
$3,505
$3.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,723,632 |
| 2021 | $1,430,503 |
| 2022 | $1,261,029 |
| 2023 | $1,154,941 |
| 2024 | $925,210 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, et al. · Am J Transplant 2010 · Clinical Trial, Phase III, Multicenter Study
- Tacrolimus in heart transplantation.
Crespo-Leiro MG · Transplant Proc 2003 · Clinical Trial, Randomized Controlled Trial
- Topical cyclosporine in vernal keratoconjunctivitis.
Bleik JH, Tabbara KF · Ophthalmology 1991 · Clinical Trial, Randomized Controlled Trial
- Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review.
Kulthanan K, Chaweekulrat P, Komoltri C, et al. · J Allergy Clin Immunol Pract 2018 · Meta-Analysis, Systematic Review
- Renal transplantation without steroids.
Salaman JR, Gomes Da Costa CA, Griffin PJ · J Pediatr 1987 · Clinical Trial, Comparative Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.